Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 43 (15) , 1089-1115
- https://doi.org/10.2165/00003088-200443150-00003
Abstract
Bosentan, a dual endothelin receptor antagonist, is indicated for the treatment of patients with pulmonary arterial hypertension (PAH). Following oral administration, bosentan attains peak plasma...Keywords
This publication has 72 references indexed in Scilit:
- Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and SimvastatinClinical Pharmacokinetics, 2003
- Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertensionExpert Opinion on Investigational Drugs, 2001
- Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transportEuropean Journal of Pharmaceutical Sciences, 2000
- Endothelin-receptor antagonists: current and future perspectivesDrug Discovery Today, 2000
- Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary HypertensionCirculation, 2000
- Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 1999
- Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-GlycoproteinPharmaceutical Research, 1999
- Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacksPAIN®, 1996
- Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failureThe Lancet, 1995
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992